Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows, surgeons and other healthcare providers involved in the treatment of colorectal cancer.
Learning Objectives
Upon completion of this activity, participants should be able to
- Develop an understanding of validated biomarkers of response (eg, RAS mutations, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, HER2 overexpression, BRAF V600E mutations) found in patients with colorectal cancer (CRC), and consider the implications for molecular testing and clinical care.
- Optimize the use of neoadjuvant and adjuvant systemic therapy for patients with localized CRC, considering various clinical and biological factors, such as age, performance status, stage, MSI/MMR status, and the potential relevance of molecular residual disease.
- Formulate a plan to guide the selection and sequencing of therapies for patients diagnosed with metastatic CRC (mCRC) with an actionable biomarker, and optimally incorporate approved targeted treatments into current clinical care.
- Evaluate the biological rationale for the use of immune checkpoint inhibitors for MSI-high/MMR-deficient localized and advanced CRC, and counsel patients regarding evidence-based and guideline-endorsed treatment recommendations.
- Recall ongoing trials evaluating novel agents and strategies for localized and advanced CRC, and use this information to refer appropriate patients for study participation.
CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.
Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1 Medical Knowledge MOC point toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.
Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Meyerhardt has no conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:
Dr Kopetz — Consulting Agreements: Agenus Inc, Amgen Inc, AmMax Bio, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Carina Biotech, Clasp Therapeutics, Cytovation ASA, Dewpoint Therapeutics, Frontier Medicines, Genentech, a member of the Roche Group, Harbinger Health, Ikena Oncology, Kestrel Therapeutics, Leap Therapeutics Inc, Marengo Therapeutics, Merck, Mirati Therapeutics Inc, Pfizer Inc, Replimune, Revolution Medicines, Roche Laboratories Inc, SageMedic Corporation, Servier Pharmaceuticals LLC, Sibylla Biotech, T-Cypher Bio, Tachyon Therapeutics, Tempus, Xaira Therapeutics, Zentalis Pharmaceuticals; Contracted Research: Amgen Inc, BioMed Valley Discoveries, Boehringer Ingelheim Pharmaceuticals Inc, BridgeBio, Bristol Myers Squibb, Cardiff Oncology, Daiichi Sankyo Inc, EMD Serono Inc, Frontier Medicines, Genentech, a member of the Roche Group, Guardant Health, Jazz Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, Pfizer Inc, Zentalis Pharmaceuticals.
MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
Supporters
This activity is supported by educational grants from GSK and Natera Inc.
